Czech biotech SOTIO appoints experienced immune-oncology doc as new CMO

pharmafile | February 5, 2019 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Czech biotech SOTIO has announced the appointment of Dr Harald Fricke as the firm’s Chief Medical Officer (CMO).

Dr Fricke, who brings to the role more than 30 years of experience in the field of immune-oncology research and clinical development of new cancer therapies, will be responsible for clinical strategy and leading the company’s clinical stage pipeline.

Dr Fricke graduated from the Medical University of Lübeck and later from the Weizmann Institute of Science in Israel from 1987-1990. He subsequently gained his habilitation (a professorship qualification necessary for teaching roles in many European countries) from Ludwig-Maximilians-University in Munich in 1996.

Radek Spisek, CEO of SOTIO, commented: “We are very excited to welcome Dr. Fricke to our team. His long-term experience and successful track record in scientific research, drug development and regulatory strategy in immune-oncology will be extremely valuable for SOTIO.”

Dr Fricke has worked at a number of large firms including Smithkline beecham, GlaxoSmithKline, Baxter and Fresenius Biotech where he held management positions with increasing responsibility for global R&D.

In 2006, Dr Fricke co-founded Apogenix in Heidelberg, Germany which resulted in an extensive portfolio of immune-oncology pipeline candidates. Autoimmunity and tumour immunology are Dr Fricke’s areas of expertise.

Commenting on his appointment, Dr. Fricke said: “I am joining SOTIO at a pivotal moment as SOTIO is initiating two important clinical trials: the first-in-human study with SO-C101, SOTIO’s IL-15 superagonist, and the pivotal trial with DCVAC/OvCa, an active cellular immunotherapy product for patients with ovarian cancer hold great promise. I am impressed by the clinical results of the two Phase II trials with DCVAC in 1st and 2nd line ovarian cancer and the preclinical data of SO-C101. I am excited to join SOTIO’s team and look forward to contributing with my knowledge and experience to advance SOTIO’s broad product pipeline.”

Related Content

No items found

Latest content